Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza

Bibliography

• Deng G, Li Z, Tian G, The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci USA 2004;101:10452-7
   PubMed Web of Science ®Google Scholar
• Available from: http://www.who.int/influenza/human_animal_interface/EN_GIP_20120810CumulativeNumberH5N1cases.pdf
   Google Scholar
• Li C, Hatta M, Nidom CA, Reassortment between avian H5N1 and H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci USA 2010;107:4687-92
   PubMed Web of Science ®Google Scholar
• Imai M, Watanabe T, Hatta M, Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012;486:420-8
   PubMed Web of Science ®Google Scholar
• Herfst S, Schrauwen EJ, Linster M, Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012;336:1534-41
   PubMed Web of Science ®Google Scholar
• Russell CA, Fonville JM, Brown AE, The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012;336:1541-7
   PubMed Web of Science ®Google Scholar
• Available from: http://www.who.int/influenza/surveillance_monitoring/updates/2012_08_17_influenza_global_circulation.pdf
   Google Scholar
• Gillim-Ross L, Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 2006;19:614-36
   PubMed Web of Science ®Google Scholar
• Girard MP, Katz JM, Pervikov Y, Report of the 7th meeting on Evaluation of pandemic influenza vaccines in clinical trials. World Health Organization; Geneva: 2011
   Google Scholar
• Stohr K. Vaccinate before the next pandemic? Nature 2010;465:161
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A, Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-43
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG, Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191:1210-15
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Colegate A, Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21:1687-93
   PubMed Web of Science ®Google Scholar
• Galli G, Hancock K, Hoschler K, Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009;106:7962-7
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Hoschler K, Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008;359:1631-3
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Nicolay U, Lindert K, MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009;27:6959-65
   PubMed Web of Science ®Google Scholar
• Black S, Della Cioppa G, Malfroot A, Safety of MF59-adjuvanted versus non-adjuvanted vaccines in children and adolescents: an integrated analysis. Vaccine 2010;28:7331-6
   PubMed Web of Science ®Google Scholar
• Schultze V, D'Agosto V, Wack A, Safety of MF59 adjuvant. Vaccine 2008;26:3209-22
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 2011;7:539-48
   PubMed Web of Science ®Google Scholar
• Cristiani C, Tucconi M, Pepe P, Safety of MF59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. Vaccine 2011;29:3443-8
   PubMed Web of Science ®Google Scholar
• Parretta E, Ianniello B, Ferrazin F, Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine 2011;29:3708-13
   PubMed Web of Science ®Google Scholar
• Van Puijenbroek EP, van Grootheest AC. Monitoring adverse events of vaccines against Mexican flu. Int J Risk Saf Med 2011;23:81-7
   Google Scholar
• Heikkinen T, Young J, Van Beek E, Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012;207(3):177; e1-8
   PubMed Web of Science ®Google Scholar
• Tsai T, Kyaw MH, Novicki D, Exposure to MF59-adjuvanted influenza vaccines during pregnancy – a retrospective analysis. Vaccine 2010;28:1877-80
   PubMed Web of Science ®Google Scholar
• Alberini I, Del Tordello E, Fasolo A, Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 2009;27:5998-6003
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Edwards KM, Dekker CL, Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008;197:667-75
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F, MF59®-adjuvanted. H5N1 vaccine induces immunologica memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009;6:e4364
   Google Scholar
• Fragapane E, Gasparini R, Schioppa F, A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 2010;17:1817-19
   PubMedGoogle Scholar
• Vesikari T, Forsten A, Herbinger KH, Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012;30:1388-96
   PubMed Web of Science ®Google Scholar
• Beran J, Abdel-Messih IA, Raupachova J, A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week intervals between first and second doses. Clin Ther 2010;32:2186-97
   PubMed Web of Science ®Google Scholar
• Lopez P, Caicedo Y, Sierra A, Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J Infect Dis 2011;203:1719-28
   PubMedGoogle Scholar
• Galli G, Medini D, Borgogni E, Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009;106:3877-82
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R. Novel strategies for improved vaccines for the elderly: the example of influenza. In: Thiel A, editor. Immunosenescence, Birkhaeuser advances in infectious diseases. Springer; Basel: 2012. p. 201-27
   Google Scholar
• Mannino S, Villa M, Apolone G, Effectiveness of adjuvanted influenza vaccination in elderly subjects in Northern Italy. Am J Epidemiol 2012;176(6):527-33
   PubMed Web of Science ®Google Scholar
• Maue AC, Yager EJ, Swain SL, T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol 2009;30:301-5
   PubMed Web of Science ®Google Scholar
• Gioia C, Castilletti C, Tempestilli M, Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008;14:121-8
   PubMed Web of Science ®Google Scholar
• Nair H, Brooks WA, Katz M, Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-abalysis. Lancet 2011;378:1917-30
   PubMed Web of Science ®Google Scholar
• Khandaker G, Dierig A, Rashid H, Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009. Influenza Other Respir Viruses 2011;5:148-56
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti A, Harnden A, Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008;2:CD004879
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies – United States. Morb Mortal Wkly Rep 2012;61:237-41
   PubMedGoogle Scholar
• Available from: http://www.cidrap.umn.edu/cidrap/content/influenza/general/news/aug1712variant.html
   Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-71
   PubMed Web of Science ®Google Scholar
• Vesikari T, Groth N, Karvonen A, MF59-adjuvanted influenza vaccine (Fluad®) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009;27:6291-5
   PubMed Web of Science ®Google Scholar
• Vesikari T, Knuf M, Wutzler P, Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011;365:1406-16
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011;30:1081-5
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Li KF, Chui CS, Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18:274-80
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Tilman S, Immunogenicity and safety of MF59-adjuvanted H5N1 vaccine from infancy to adolescence. Pediatrics 2010;126:e762-70
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Borkowski A, Homologous and heterologous antibody responses to a one-year booster dose of an MF59-adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 2012;8:921-8
   PubMed Web of Science ®Google Scholar
• Atmar RL, Keitel WA, Patel SM, Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006;43:1135-42
   PubMed Web of Science ®Google Scholar
• Bresson JL, Perronne C, Launay O, Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/204 (H5N1) vaccine: phase I randomized trial. Lancet 2007;367:1657-64
   Web of Science ®Google Scholar
• Khurana S, Chearwae W, Castellino F, MF59-adjuvanted vaccines expand antibody repertoires targeting protective sites of pandemic H5N1 influenza virus. Sci Transl Med 2010;2:15ra5
   PubMed Web of Science ®Google Scholar
• Khurana S, Suguitan A Jr, Rivera Y, Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and siagnostic tools. PLoS Med 2009;6:e1000049- doi:10.371
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza viruses. Sci Transl Med 2011;3:85ra48
   PubMed Web of Science ®Google Scholar
• Meier S, Bel M, L'huillier A, H1N1 Epidemiology Study Group of Geneva. Antibody response to natural influenza A/H1N1/09 disease of following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 2011;29:3548-57
   PubMed Web of Science ®Google Scholar
• Elkayam O, Amir S, Mendelson E, Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res 2011;63:1062-7
   PubMed Web of Science ®Google Scholar
• Soonawala D, Rimmelzwaan GF, Gelink LB, Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011;6:e16496
   PubMed Web of Science ®Google Scholar
• Esposito S, Tagliaferri L, Daleno C, Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 2011;29:1677-82
   PubMed Web of Science ®Google Scholar
• Paschke R, Pollok M, Geiger H, Increased immunogenicity with an MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in renal transplant recipients. J Prev Med Hyg 2003;44:79-84
   Google Scholar
• Esposito S, Meregalli E, Daleno C, An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza/AH1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011;26:2018-24
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009;9:1057-71
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Adjuvant System AS03 containing a-tocopherol modulates innate immune response and leads to improved acquired immunity. Vaccine 2011;29:2461-73
   PubMed Web of Science ®Google Scholar
• Caproni E, Tritto E, Cortese M, MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol 2012;188:3088-98
   PubMed Web of Science ®Google Scholar
• Rahier JF, Papay P, Salleron J, European Crohn's and Colitis Organisation (ECCO). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60:456-62
   PubMed Web of Science ®Google Scholar
• Nohynek H, Jokinen J, Partinen M, AS03-adjuvanted A/H1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012;7:e33536
   PubMed Web of Science ®Google Scholar
• Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012;7:e33723
   PubMed Web of Science ®Google Scholar
• Tsai TF, Crucitti A, Nacci P, Exploration of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011;43:702-6
   PubMed Web of Science ®Google Scholar
• Dormitzer PR. Cell culture-derived influenza vaccines. In: Rappuoli R, Del Giudice G, editors. Influenza vaccines for the future. 2nd edition. Birkhaeuser advances in infectious diseases Springer; Basel: 2011. p. 293-312
   Google Scholar
• Kapteyn JC, Porre AM, de Rond EJ, HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009;27:1468-77
   PubMedGoogle Scholar
• Verity EE, Camuglia S, Agius CT, Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA. Influenza Other Respir Viruses 2011;6:101-9
   Web of Science ®Google Scholar
• Rappuoli R, Dormitzer PR. Influenza: option to improve pandemic preparation. Science 2012;336:1531-3
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, De Serres G, Cross-reactive and vaccine-induced antibody to emerging swine influenza A(H3N2)v. J Infect Dis 2012; doi: 10.1093/infdis/jis500
   Web of Science ®Google Scholar
• Anthony SJ, St Leger JA, Pugliares K, Emergence of fatal avian influenza in New England harbor seals. MBio 2012;3: pii e00166-12
   PubMed Web of Science ®Google Scholar
• Czajka H, Unal S, Ulusoy S, A phase II, randomized clinical trial to demonstrate non-inferiority of low-dose MF59®-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. J Prev Med Hyg 2012;53; In press
   PubMedGoogle Scholar